文献速递消化道肿瘤放疗放疗物理与技术

不可切除胰腺癌放疗与化疗的当代应用及结局

Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2022-04-19

该研究分析了美国5624例不可切除非转移性胰腺癌患者,比较常规分割放疗、立体定向体部放疗与单纯化疗的使用趋势、胃肠道并发症及医疗支出;放疗使用比例下降,立体定向体部放疗使用增加,加用放疗与更多胃肠道出血、狭窄和瘘相关,立体定向体部放疗的医疗支出最高。

要点

  • 老年患者放疗使用比例从55%降至45%,年轻患者从52%降至47%(趋势P<0.001)。
  • 近年立体定向体部放疗在老年和年轻患者中分别增至10%和12%。
  • 加用放疗与胃肠道出血、狭窄和瘘事件增加3%至9%相关(所有P≤0.05)。

核心结论

  • 真实世界治疗趋势显示不可切除胰腺癌对放疗的选择性增加,但立体定向体部放疗的应用和并发症谱的改善趋势是优化当前使用和获益的机会。

研究设计与样本

  • 分析5624例非转移性不可切除胰腺癌患者,包括2522例年龄>65岁、2006-2013年诊断的Medicare关联数据患者和3102例年龄<65岁、2006-2016年诊断的MarketScan数据患者,比较常规分割放疗、立体定向体部放疗与单纯化疗。

主要发现

  • 放疗使用比例在老年患者中从55%降至45%(2006-2013年),在年轻患者中从52%降至47%(2006-2016年),趋势P均<0.001。
  • 在放疗患者中,近年立体定向体部放疗使用在老年患者中增至10%、在年轻患者中增至12%(趋势P=0.04和<0.001)。
  • 加用放疗与更频繁的胃肠道出血、狭窄和瘘相关(超额事件Δ=+3%至9%,所有P≤0.05)。
  • 年轻患者中立体定向体部放疗与常规分割放疗的胃肠道并发症无差异(所有比较P>0.05);老年患者中1-4次立体定向体部放疗较常规分割放疗并发症增加(P<0.05),但5次立体定向体部放疗无差异(P=0.72)。
  • 立体定向体部放疗的医疗支出在US Medicare和雇主保险中均高于常规分割放疗或化疗(P均<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We assessed radiation treatment (RT) use and complications for unresectable pancreatic cancer in the US, comparing conventionally fractionated (CFRT) and stereotactic body radiation treatment (SBRT) to inform real-world expected outcomes and practice. MATERIAL AND METHODS: We analyzed 5,624 patients with non-metastatic, unresectable pancreatic cancer (2,522 older patients age > 65, diagnosed 2006-2013 in Medicare linked data; and 3,102 younger patients age < 65, diagnosed 2006-2016 in MarketScan data), comparing CFRT vs. SBRT vs. chemotherapy alone. Cochran-Armitage tested temporal trends. Fisher's Exact Test and proportional hazards models compared gastrointestinal (GI) complications. Healthcare payments (Consumer Price Index adjusted to 2015) through 12 months were compared using generalized linear regression models with log link and gamma distribution. RESULTS: RT use declined from 55% to 45% of older patients (2006-2013) and 52% to 47% of younger patients (2006-2016) (Ptrend < 0.001 both). Among RT patients, SBRT use increased to 10% of older patients and 12% of younger patients in the most recent years (Ptrend = 0.04 and < 0.001 respectively). Addition of RT was associated with more frequent GI bleeds, strictures, and fistulas (Δ= +3% to 9% excess events, all P ≤ 0.05). Temporal patterns suggested decreasing complications over time (Ptrend = 0.05 and 0.05 for older and younger patients). Among younger patients, there was no difference in GI complications for SBRT vs. CFRT (P > 0.05, all comparisons). Among older patients, increased complications were seen for SBRT in 1-4 fractions vs. CFRT (P < 0.05), but not SBRT in 5 fractions (P = 0.72). Healthcare payments were greatest for SBRT when compared with CFRT or chemotherapy under US Medicare (P < 0.001) and employer-based insurance (P < 0.001). CONCLUSION: Real-world treatment has shifted toward more selectivity for RT in unresectable pancreatic cancer. However, SBRT uptake and improving trends in complications profiles represent opportunities to optimize current use and benefit. Findings are applicable to inform future comparative and cost effectiveness models of RT for this disease.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Moningi S, Lei X, Fang P, et al. Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. Clin Transl Radiat Oncol. 2022. PMID: 35510142. doi:10.1016/j.ctro.2022.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。